Stigma and Quality of Life in Patients With Advanced Lung Cancer.

Stigma and Quality of Life in Patients With Advanced Lung Cancer. Oncol Nurs Forum. 2019 May 01;46(3):318-328 Authors: Johnson LA, Schreier AM, Swanson M, Moye JP, Ridner S Abstract OBJECTIVES: To identify groups of participants with high and low levels of stigma and to examine the influence of stigma on social support, social constraints, symptom severity, symptom interference, and quality of life (QOL). SAMPLE & SETTING: 62 individuals with lung cancer were identified and recruited from a comprehensive cancer center in the southeastern United States. METHODS & VARIABLES: Participants completed a questionnaire that included demographic information and measures of stigma, symptom severity and interference, social support, social constraints, and QOL. IBM SPSS Statistics TwoStep Cluster Analysis was used to identify high- and low-stigma groups. Independent sample t tests were used to compare differences between the groups. RESULTS: 22 participants had a high level of stigma; they had significantly higher symptom severity on feeling distressed, problems remembering things, and feeling sad, and greater symptom interference related to mood, relations with others, and enjoyment of life. Participants also had significantly higher levels of social support and lower social constraints. Stigma was significantly related to lower levels of QOL. IMPLICATIONS FOR NURSING: Nurses should be aware that stigma may influence various factors thr...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research

Related Links:

CONCLUSIONS circ_100395 appears to be a promising therapeutic target for liver cancer. PMID: 31421050 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Conditions:   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer Interventions:   Drug: Durvalumab;   Procedure: Surgery;   Radiation: Radiotherapy Sponsors:   Alliance Foundation Trials, LLC.;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Lung Non-Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJC C v8;   Stage IIB Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8 I...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: The number of patients with COPD registered in primary health care was similar in all investigated years. Lung cancer as comorbidity was found in a significantly smaller number of these patients. PMID: 31424648 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
CONCLUSIONS: Higher expression of microRNA-19a promotes proliferative and migratory abilities of NSCLC cells by target inhibiting PTEN expression. PMID: 31424647 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Authors: P Sotiropoulos G, Kotopouli M, Karampela I, Christodoulatos GS, Antonakos G, Marinou I, Vogiatzakis E, Lekka A, G Papavassiliou A, Dalamaga M Abstract PURPOSE: Plasminogen activator inhibitor-1 (PAI-1) participates in thrombotic, fibrinolytic, inflammatory and metabolic cascades. Since previous studies have focused on tissue and blood level concentrations, our goal was to investigate for the first time the independent relationship between plasma PAI-1 activity in resectable non small cell lung cancer (NSCLC) taking into consideration its several interfaces and study its diagnostic and prognostic potential....
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
CONCLUSIONS: Chrysoeriol considerably and selectively suppresses the growth of lung cancer in vitro and in vivo and may prove beneficial in the management of this disease. PMID: 31424645 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Authors: Liu S, Chen J, Zhang T, Chen H Abstract PURPOSE: Accounting for 25% of all cancers and 20% of the cancer related-mortality, lung cancer is one of the devastating types of malignancies. The main obstacles for successful lung cancer manipulation include late diagnosis, dearth of safer chemotherapy and lack of potent therapeutic targets. Evidence indicates that microRNAs (miRs) may prove essential therapeutic targets for the management of deadly diseases, including cancer. Herein the role of miR-133 was investigated in lung cancer and the therapeutic potential of miR-133 was explored. METHODS: qRT-PCR was...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
CONCLUSIONS: H19 polymorphism rs2067051 and rs217727 might influence NSCLC susceptibility and the mechanism warrants further exploration. PMID: 31424642 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
CONCLUSIONS: In conclusion, the current results strongly indicate that Curzerenone may prove a potential anticancer drug candidate against drug-resistant lung cancer. PMID: 31424641 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Nurses | Nursing | Statistics | USA Health